Replying to:
We are very proud to shaer here a comment written by Robert Kerbel from the Department of Medical Biophysics, Biological Sciences Platform, Sunnybrook Research Institute, University of Toronto, Canada & Nicolas André from the Metronomics Global Health Initiative, Children Hospital of La Timone, AP-HM, Aix Marseille Université, Marseille, France taht has been publisehd in the Lancet as a comment for a randomized trial (Chen Y-P Liu X Zhou Q et al.Metronomic capecitabine as adjuvant therapy (...)